Introduction To date, there is no approved treatment for sudden sensorineural hearing loss (SSNHL). Glucocorticoids are recommended in the guidelines, but the therapeutic benefit is unclear. AC102, a newly developed molecule, clearly outperformed glucocorticoids in preclinical hearing loss models. In a phase 1 study, AC102 (intratympanic) was proven to be safe and well tolerated. A phase 2 study is currently being conducted to investigate the efficacy of AC102.
No takes yet. Share an insight, caveat, or question.
Pennings et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: